Sesen Bio, Inc.

Sesen Bio, Inc. is a biotechnology company focused on developing innovative therapeutic solutions for patients with cancer through targeted treatments that enhance efficacy while minimizing side effects. Sesen Bio, Inc. specializes in the development of targeted therapies for cancer treatment.

Founded in 2010, the company is headquartered in Cambridge, US. It has operated independently and does not have any reported subsidiaries. The company was formed through the efforts of a dedicated team of professionals in the biotech field, aiming to address specific oncological challenges. The CEO is Dr.

Thomas Cannell, who has extensive experience in biotechnology and pharmaceuticals. Sesen Bio has successfully completed multiple funding rounds, including a recent SERIES C round, raising significant capital to support its research and development initiatives. Sesen Bio, Inc. offers a range of innovative biopharmaceutical products designed to treat various types of cancer.

Their primary product candidates focus on monoclonal antibody therapies that target cancer cells, aiming to improve patient outcomes while reducing the toxicity commonly associated with traditional cancer treatments. The company’s products are designed for use in clinical settings and are supported by ongoing clinical trials to ensure their effectiveness and safety for patients across different demographics and regions. The company generates its revenue through the development and commercialization of its therapeutic products, primarily derived from partnerships with healthcare providers and pharmaceutical companies. Revenue streams are enhanced by potential milestones and royalties linked to successful product launches and market penetration.

Although specific pricing details for their therapeutics are proprietary, the company’s financial structure is designed to support sustained growth and innovation within the oncology market. Sesen Bio, Inc. is working on expanding its product pipeline, with new therapies under development expected to enter clinical trials in the coming year. The company aims to broaden its market presence by targeting Europe and Asia as key regions for expansion by 2025.

Recent funding from its SERIES C round will be utilized to support these initiatives, facilitating advanced clinical trials and the regulatory approval process necessary for market entry in these new territories.